Bayer’s (BAYN GY) Xofigo plus Enzalutamide demonstrates significant overall survival benefit in Peace-3 trial in patients with metastatic castration-resistant prostate cancer with bone metastases
Context
Bayer's positive results from the Peace-3 trial for Xofigo and Enzalutamide indicate a significant survival benefit in a serious cancer patient population. This development could enhance investor sentiment towards Bayer’s pharmaceutical portfolio and potentially influence stock performance, particularly as it positions the company favorably within the competitive oncology space.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#GERMANY#EUROPE#BAYER AG#BAYN.GY#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BAYN#EURO STOXX 50#DAX 40 INDEX